2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Breast Neoplasms
2
Renal Insufficiency
1
Prostatic Neoplasms
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Mastocytosis, Systemic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Renal Cell
1
Carcinoma, Medullary
1
Burkitt Lymphoma
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Blood Protein Disorders
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Advanced Cancer
1
Interventions
vandetanib
14
cabozantinib
9
selpercatinib
6
Sorafenib
5
Everolimus
5
pralsetinib
3
Magnetic Resonance Spectroscopy
3
Capecitabine
3
sargramostim
2
lutetium Lu 177 dotatate
2
lenvatinib
2
Trastuzumab
2
Thyroidectomy
2
Temozolomide
2
Sunitinib
2
Specimen Handling
2
Octreotide
2
High-Energy Shock Waves
2
Gefitinib
2
Doxorubicin
2
yeast-CEA vaccine
1
veliparib
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sacubitril and valsartan sodium hydrate drug combination
1
rovalpituzumab tesirine
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Medullary
×
Ranitidine
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled